This trial is testing the long-term safety of a cancer drug.
7 Primary · 0 Secondary · Reporting Duration: From Day 1 up to 100 Days after discontinuation of treatment
Experimental Treatment
800 Total Participants · 2 Treatment Groups
Primary Treatment: Nivolumab · No Placebo Group · Phase 2
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: